Related Experiment Videos
Increased glomerular nitric oxide synthesis in gentamicin-induced renal failure
L Rivas-Cabañero1, A Montero, J M López-Novoa
1Departamento de Fisiologia y Farmacologia, Facultad de Medicina, Universidad de Salamanca, Spain.
European Journal of Pharmacology
|January 3, 1994
Summary
Gentamicin-induced renal failure in rats significantly increases nitric oxide (NO) production in glomeruli. This heightened NO leads to elevated cyclic GMP (cGMP) levels, indicating a potential mechanism in kidney damage.
Area of Science:
- Nephrology
- Biochemistry
- Pharmacology
Background:
- Gentamicin is an antibiotic known to cause nephrotoxicity.
- Nitric oxide (NO) plays a complex role in renal function and disease.
- Cyclic guanosine monophosphate (cGMP) is a key second messenger involved in cellular signaling.
Purpose of the Study:
- To investigate the role of nitric oxide (NO) synthesis in gentamicin-induced renal failure.
- To quantify changes in glomerular cyclic guanosine monophosphate (cGMP) levels in response to NO modulation.
- To explore the functional consequences of altered NO signaling in damaged glomeruli.
Main Methods:
- Isolation of renal glomeruli from normal and gentamicin-treated rats.
- Incubation of glomeruli with agents affecting NO synthesis (e.g., acetylcholine, bradykinin, NG-nitro-L-arginine-methyl ester).
- Measurement of glomerular cGMP levels using radioimmunoassay.
Main Results:
- Glomeruli from gentamicin-treated rats exhibited significantly higher basal cGMP levels compared to normal glomeruli.
- Acetylcholine and bradykinin stimulated cGMP accumulation in both normal and gentamicin-treated glomeruli.
- NG-nitro-L-arginine-methyl ester, an NO synthesis inhibitor, blocked NO-mediated cGMP increases in normal glomeruli but decreased cGMP below basal levels in gentamicin-treated glomeruli.
Conclusions:
- Gentamicin-induced renal failure is associated with increased glomerular nitric oxide (NO) production.
- The NO/cGMP pathway is altered in gentamicin nephropathy, suggesting a role in the disease process.
- These findings highlight potential therapeutic targets for mitigating gentamicin-induced kidney damage.